Chissov V I, Sokolov V V, Filonenko E V, Menenkov V D, Zharkova N N, Kozlov D N, Polivanov Iu N, Prokhorov A M, Pykhov R L, Smirnov V V
Khirurgiia (Mosk). 1995(5):37-41.
During clinical trials of photodynamic therapy (PDT) the tissue fluorescence spectra under 510 nm laser excitation were recorded in 22 patients with tumors of the lungs, larynx, skin, gastric and esophageal carcinoma, and cancer of the gynecological organs before (autofluorescence) and after drug administration. A spectroscopic fluorescence detection system, developed at the General Physics Institute, Russian Academy of Sciences, was applied for tumor diagnostics. The system has been used for clinical fluorescence diagnostics with the aid of HPD-type photosensitizer Photogem (Moscow Institute of High Chemical Technologies) marked by selective retention in malignant tumors. Methods and equipment for spectra analysis aimed at estimating drug distribution in the near-surface layers of tissues, determining the tumor boundaries before photodynamic treatment, as well as studying drug pharmaco kinetics have been developed and tested. The results demonstrate the possibility of tumor detection by fluorescence even in low selectivity of drug accumulation which appears to be dependent on the stage and type of the disease and the organ involved.
在光动力疗法（PDT）的临床试验中，在22例患有肺癌、喉癌、皮肤癌、胃癌、食管癌和妇科器官癌的患者中，记录了在510nm激光激发下给药前（自发荧光）和给药后的组织荧光光谱。俄罗斯科学院普通物理研究所研制的光谱荧光检测系统被用于肿瘤诊断。该系统借助以在恶性肿瘤中选择性滞留为特征的HPD型光敏剂Photogem（莫斯科高化学技术研究所）用于临床荧光诊断。已经开发并测试了用于光谱分析的方法和设备，旨在评估药物在组织近表层的分布、确定光动力治疗前的肿瘤边界以及研究药物药代动力学。结果表明，即使在药物积累选择性较低的情况下，也有可能通过荧光检测肿瘤，而药物积累的选择性似乎取决于疾病的阶段和类型以及所涉及的器官。
